This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shafren, D. R. Articles by Barry, R. D. Search for Related Content PubMed PubMed Citation Articles by Shafren, D. R. Articles by Barry, R. D.

Systemic Therapy of Malignant Human Melanoma Tumors by a Common Cold-Producing Enterovirus, Coxsackievirus A21

¹The Picornaviral Research Unit, Biomedical Science, Faculty of Health, The University of Newcastle, Newcastle, New South Wales, Australia;² ViroTarg Pty. Ltd., Industry Development Centre, Newcastle, New South Wales, Australia; and³ Immunology and Oncology Unit, Mater Hospital, Newcastle, New South Wales, Australia

ABSTRACT

Purpose: The incidence of malignant melanoma continues to increase worldwide; however, treatment of metastatic melanoma remains unsatisfactory, and there is an urgent need for development of effective targeted therapeutics. A potential biological target on the surface of malignant melanoma cells is the up-regulated expression of intercellular adhesion molecule (ICAM)-1 and decay-accelerating factor (DAF), relative to surrounding benign tissue. Coxsackievirus A21 (a common cold virus) targets and destroys susceptible cells via specific viral capsid interactions with surface-expressed virus receptors comprising ICAM-1 and DAF.

Experimental Design: The oncolytic capacity of a genetically unmodified wild-type common cold-producing human enterovirus (Coxsackievirus A21, CAV21) was assessed against in vitro cultures and in vivo xenografts of malignant human melanoma cells.

Results: In vitro studies established that human melanoma cells endogenously express elevated levels of ICAM-1/DAF and were highly susceptible to rapid viral oncolysis by CAV21 infection, whereas ICAM-1/DAF-expressing peripheral blood lymphocytes were refractile to infection. In vivo studies revealed that the tumor burden of nonobese diabetic severe combined immunodeficient mice bearing multiple s.c. melanoma xenografts was rapidly reduced by oncolysis mediated by a single administration of CAV21. The antitumor activity of CAV21 was characterized by highly efficient systemic spread of progeny CAV21, with oncolysis of tumors also occurring at sites distant to the primary site of viral administration.

Conclusions: Overall, the findings presented herein demonstrate an important proof of principle using administration of replication-competent CAV21 as a potential biological oncolytic agent in the control of human metastatic melanoma.

This article has been cited by other articles:

				P. S. Reddy, K. D. Burroughs, L. M. Hales, S. Ganesh, B. H. Jones, N. Idamakanti, C. Hay, S. S. Li, K. L. Skele, A.-J. Vasko, et al. Seneca Valley Virus, a Systemically Deliverable Oncolytic Picornavirus, and the Treatment of Neuroendocrine Cancers J Natl Cancer Inst, November 7, 2007; 99(21): 1623 - 1633. [Abstract] [Full Text] [PDF]

				Q. Zhang, Y. A. Yu, E. Wang, N. Chen, R. L. Danner, P. J. Munson, F. M. Marincola, and A. A. Szalay Eradication of Solid Human Breast Tumors in Nude Mice with an Intravenously Injected Light-Emitting Oncolytic Vaccinia Virus Cancer Res., October 15, 2007; 67(20): 10038 - 10046. [Abstract] [Full Text] [PDF]

				M. J.V. Vaha-Koskela, J. P. Kallio, L. C. Jansson, J. E. Heikkila, V. A. Zakhartchenko, M. A. Kallajoki, V.-M. Kahari, and A. E. Hinkkanen Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice. Cancer Res., July 15, 2006; 66(14): 7185 - 7194. [Abstract] [Full Text] [PDF]

				Y. V. Svitkin, B. Herdy, M. Costa-Mattioli, A.-C. Gingras, B. Raught, and N. Sonenberg Eukaryotic Translation Initiation Factor 4E Availability Controls the Switch between Cap-Dependent and Internal Ribosomal Entry Site-Mediated Translation Mol. Cell. Biol., December 1, 2005; 25(23): 10556 - 10565. [Abstract] [Full Text] [PDF]

				E. S. Johansson, L. Xing, R. H. Cheng, and D. R. Shafren Enhanced Cellular Receptor Usage by a Bioselected Variant of Coxsackievirus A21 J. Virol., November 15, 2004; 78(22): 12603 - 12612. [Abstract] [Full Text] [PDF]